On August 29, 2025, DuPont entered into a Transaction Agreement with ARC Falcon Holdings, L.P. and New Arclin U.S. Holding Corp., pursuant to which the company has agreed to sell its Aramids business (Kevlar® and Nomex®) to Arclin in a transaction valuing the business at approximately $1.8 billion.

1. 01

   On August 29, 2025, DuPont entered into a Transaction Agreement with ARC Falcon Holdings, L.P. and New Arclin U.S. Holding Corp., pursuant to which the company has agreed to sell its Aramids business (Kevlar® and Nomex®) to Arclin in a transaction valuing the business at approximately $1.8 billion.

2. 02

   At the closing of the transaction, DuPont will receive pre-tax cash proceeds of approximately $1.2 billion, subject to customary transaction adjustments, a note receivable of $300 million, and a non-controlling common equity interest in the future Arclin company currently valued at $325 million. The company said this interest is expected to represent an approximate 17.5% stake at the time of closing.

3. 03

   DuPont said consummation of the transaction is subject to the satisfaction of customary mutual closing conditions, including the absence of an injunction in certain agreed jurisdictions that would prohibit consummation of the transaction and the expiration or termination of the required waiting, notice or review periods and approvals or clearances under the Hart-Scott-Rodino Act and certain other approvals under non-U.S. regulatory laws, including the European Union, Japan, China, South Korea and the United Kingdom.

4. 04

   The company said DuPont and Buyer may terminate the Transaction Agreement if the transaction is not consummated on or before May 1, 2026. The termination right is subject to two extensions of 2 months each if all closing conditions have been satisfied other than those related to the receipt of regulatory approvals and those to be satisfied at closing.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.